{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:02Z","timestamp":1789556582611,"version":"build-2803163510"},"reference-count":186,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI150334"],"award-info":[{"award-number":["AI150334"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cancer immunotherapy has improved outcomes across many tumor types, but primary and acquired resistance, tumor heterogeneity and a shortage of safe targets remain unresolved. Part of this gap arises because tumor cells evade immune recognition not only through genomic mutation but also through post-transcriptional mRNA processing, a network comprising 5\u2032 capping, splicing, alternative polyadenylation (APA), RNA editing, epitranscriptomic modification, nonsense-mediated decay (NMD), RNA stability and translational control. These processes govern antigen presentation, transcript degradation, checkpoint expression and the suppression of innate immune sensing. Here we examine how mRNA processing can extend the target space of cancer immunotherapy. We consider alternative splicing as a source of tumor-specific isoforms, public neoantigens and chimeric antigen receptor (CAR) or T-cell receptor (TCR)-based targets; the effect of APA and 3\u2032UTR remodeling on checkpoints such as PD-L1; the role of m6A, ac4C and other epitranscriptomic marks in antigen presentation, interferon signaling and the tumor microenvironment; the contribution of ADAR1-mediated editing to immunotherapy resistance through suppressed dsRNA and Z-RNA sensing; and the function of NMD as an antigen filter. We also review the discovery technologies that make these targets accessible, and assess the current state of clinical translation, including agent development, target specificity, patient selection, biomarkers and safety.<\/jats:p>\n                  <jats:p>mRNA processing-derived targets offer new sources of antigens, biomarkers and combination strategies in tumors with low mutational burden or refractory to checkpoint blockade. Realizing this will require validation of RNA-level candidates at the protein and HLA-peptide level, together with attention to tumor-normal specificity, HLA restriction, tumor heterogeneity and toxicity.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1889279","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:14:16Z","timestamp":1789553656000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["mRNA processing in cancer immunotherapy: emerging targets, resistance mechanisms, and therapeutic opportunities"],"prefix":"10.3389","volume":"17","author":[{"given":"Yunus","family":"Yukselten","sequence":"first","affiliation":[{"name":"Section of Infectious Diseases, Department of Internal Medicine, Yale University","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haseeb","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Internal Medicine, Yale University","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Shoultout","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Internal Medicine, Yale University","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzair","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Internal Medicine, Yale University","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Masood","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Internal Medicine, Yale University","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Sutton","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Internal Medicine, Yale University","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer \u2014 mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2017.05.023","article-title":"A matter of maturity: The impact of pre-mRNA processing in gene expression and antigen presentation","volume":"91","author":"Martins","year":"2017","journal-title":"Int J Biochem Cell Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1021\/bi401715v","article-title":"Structure and function of pre-mRNA 5\u2032-end capping quality control and 3\u2032-end processing","volume":"53","author":"Jurado","year":"2014","journal-title":"Biochemistry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1014","article-title":"Quantification of pre-mRNA escape rate and synergy in splicing","volume":"42","author":"Bonde","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"B6","unstructured":"Posttranscriptional regulation by proteins and noncoding RNAs\n          \n          \n            \n              Aranega\n              AE\n            \n            \n              Franco\n              D\n            \n          \n          Cham\n          Springer International Publishing\n          Congenital Heart Diseases: The Broken Heart\n          \n          2024"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221116120","article-title":"IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing","volume":"120","author":"Pan","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08552-0","article-title":"Tumour-wide RNA splicing aberrations generate actionable public neoantigens","volume":"639","author":"Kwok","year":"2025","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.immuni.2026.02.005","article-title":"Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome","volume":"59","author":"Vendramin","year":"2026","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102463","article-title":"Nonsense-mediated mRNA decay inhibits TRAF6-dependent anti-tumor immunity in colorectal cancer","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0768-9","article-title":"Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade","volume":"565","author":"Ishizuka","year":"2019","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1038\/s41467-024-47649-y","article-title":"Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression","volume":"15","author":"Shaw","year":"2024","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41368-021-00146-0","article-title":"From bulk, single-cell to spatial RNA sequencing","volume":"13","author":"Li","year":"2021","journal-title":"Int J Oral Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02345-x","article-title":"Single-cell multi-omic landscape reveals anatomical-specific immune features in adult and pediatric sepsis","volume":"27","author":"Ye","year":"2026","journal-title":"Nat Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0217-9","article-title":"Accurate circular consensus long-read sequencing improves variant detection and assembly of a human genome","volume":"37","author":"Wenger","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116781","article-title":"Immunopeptidomics combined with full-length transcriptomics uncovers diverse neoantigens","volume":"45","author":"Ishino","year":"2026","journal-title":"Cell Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2026.02.003","article-title":"From prediction to precision: how immunopeptidomics advances neoantigen discovery","volume":"12","author":"Shapiro","year":"2026","journal-title":"Trends Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41576-019-0145-z","article-title":"Alternative cleavage and polyadenylation in health and disease","volume":"20","author":"Gruber","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-052521-035330","article-title":"The proteins of mRNA modification: Writers, readers, and erasers","volume":"92","author":"Flamand","year":"2023","journal-title":"Annu Rev Biochem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.771210","article-title":"Targeting the CCL2\/CCR2 axis in cancer immunotherapy: One stone, three birds","volume":"12","author":"Fei","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","article-title":"Alternative splicing and cancer: a systematic review","volume":"6","author":"Zhang","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4239","article-title":"Intron retention is a source of neoepitopes in cancer","volume":"36","author":"Smart","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29366","article-title":"CD20 alternative splicing isoform generates immunogenic CD 4 helper T epitopes","volume":"137","author":"Vauchy","year":"2015","journal-title":"Intl J Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s11033-020-06094-y","article-title":"Alternative splicing modulates cancer aggressiveness: role in EMT\/metastasis and chemoresistance","volume":"48","author":"Roy Burman","year":"2021","journal-title":"Mol Biol Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121850","article-title":"CD44: A multifunctional mediator of cancer progression","volume":"11","author":"Hassn Mesrati","year":"2021","journal-title":"Biomolecules"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-0021","article-title":"MEN1 promotes ferroptosis by disrupting CD44 alternative splicing to suppress lung cancer","volume":"86","author":"Pan","year":"2026","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/biom14091093","article-title":"Expression of periostin alternative splicing variants in normal tissue and breast cancer","volume":"14","author":"Kanemoto","year":"2024","journal-title":"Biomolecules"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3892\/or.2018.6947","article-title":"Identification and validation of alternative splicing isoforms as novel biomarker candidates in hepatocellular carcinoma","volume":"41","author":"Wu","year":"2018","journal-title":"Oncol Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41419-019-1668-0","article-title":"Alternative splicing-derived intersectin1-L and intersectin1-S exert opposite function in glioma progression","volume":"10","author":"Shao","year":"2019","journal-title":"Cell Death Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.celrep.2018.03.052","article-title":"Systematic analysis of splice-site-creating mutations in cancer","volume":"23","author":"Jayasinghe","year":"2018","journal-title":"Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01224-2","article-title":"Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells","volume":"40","author":"North","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.06.016","article-title":"Widespread shortening of 3\u2032UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells","volume":"138","author":"Mayr","year":"2009","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1038\/ncomms6274","article-title":"Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3\u2032-UTR landscape across seven tumour types","volume":"5","author":"Xia","year":"2014","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx223","article-title":"Comprehensive characterization of alternative polyadenylation in human cancer","volume":"110","author":"Xiang","year":"2018","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1038\/s41467-024-48436-5","article-title":"Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci","volume":"15","author":"Miliotis","year":"2024","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113937","article-title":"DDX3 regulates cancer immune surveillance via 3\u2032 UTR-mediated cell-surface expression of PD-L1","volume":"43","author":"Chen","year":"2024","journal-title":"Cell Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.12853","article-title":"MicroRNA\u2010155\u20105p suppresses PD\u2010L1 expression in lung adenocarcinoma","volume":"10","author":"Huang","year":"2020","journal-title":"FEBS Open Bio"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00530-4","article-title":"Novel role of immune-related non-coding RNAs as potential biomarkers regulating tumour immunoresponse via MICA\/NKG2D pathway","volume":"11","author":"Zhang","year":"2023","journal-title":"biomark Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1093514","article-title":"The association between genetic variants at 3\u2019-UTR and 5\u2019-URR of HLA-G gene and the clinical outcomes of patients with leukemia receiving hematopoietic stem cell transplantation","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature13261","article-title":"CFIm25 links alternative polyadenylation to glioblastoma tumour suppression","volume":"510","author":"Masamha","year":"2014","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-1417","article-title":"Characterization of immune-related alternative polyadenylation events in cancer immunotherapy","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1834","article-title":"Beyond reader proteins: RNA binding proteins and RNA modifications in conversation to regulate gene expression","volume":"15","author":"Fagre","year":"2024","journal-title":"WIREs RNA"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.06.004","article-title":"m6A RNA methylation and beyond \u2013 the epigenetic machinery and potential treatment options","volume":"26","author":"Garbo","year":"2021","journal-title":"Drug Discov Today"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1709742","article-title":"METTL14 in tumor immunity: epitranscriptomic regulation and therapeutic potential","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1692608","article-title":"Decoding m6A readers: roles of YTHDF proteins in leukemogenesis and cancer immunity","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2026.117872","article-title":"Epitranscriptomic signatures of Malignancy: how RNA modifications shape breast and ovarian tumor progression","volume":"248","author":"Garg","year":"2026","journal-title":"Biochem Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2026.1756287","article-title":"Integrative multi-omic profiling of the chronically hypoxic heart: focus on m6A and m6Am epitranscriptomic regulation","volume":"14","author":"Hlavackova","year":"2026","journal-title":"Front Cell Dev Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.147657","article-title":"The interplay between post-transcriptional RNA regulation and Wnt\/\u03b2-catenin signaling in cancer: A review","volume":"328","author":"Sun","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020104514","article-title":"m6A RNA methyltransferases METTL3\/14 regulate immune responses to anti\u2010PD\u20101 therapy","volume":"39","author":"Wang","year":"2020","journal-title":"EMBO J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41467-025-67762-w","article-title":"Meta-unstable mRNAs in activated CD8+ T cells are defined by interlinked AU-rich elements and m6A mRNA methylation","volume":"17","author":"Gameiro","year":"2026","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s44319-026-00739-y","article-title":"The bladder cancer m6A landscape is defined by global methylation dilution and focal 3\u2032-UTR hypermethylation","volume":"27","author":"Koch","year":"2026","journal-title":"EMBO Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1323","article-title":"JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA","volume":"82","author":"Ni","year":"2022","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0916-x","article-title":"Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells","volume":"566","author":"Han","year":"2019","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.cell.2020.05.012","article-title":"A unified model for the function of YTHDF proteins in regulating m6A-modified mRNA","volume":"181","author":"Zaccara","year":"2020","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.607224","article-title":"YTHDF1 is a potential pan-cancer biomarker for prognosis and immunotherapy","volume":"11","author":"Hu","year":"2021","journal-title":"Front Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ebiom.2019.07.068","article-title":"N6-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer","volume":"47","author":"Jin","year":"2019","journal-title":"EBioMedicine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.835265","article-title":"Comprehensive analysis of YTHDF1 immune infiltrates and ceRNA in human esophageal carcinoma","volume":"13","author":"Liu","year":"2022","journal-title":"Front Genet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.01.001","article-title":"Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism","volume":"20","author":"Chen","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23554","article-title":"Oncogene c-Myc promotes epitranscriptome m6A reader YTHDF1 expression in colorectal cancer","volume":"9","author":"Nishizawa","year":"2018","journal-title":"Oncotarget"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1038\/s41467-019-10669-0","article-title":"m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade","volume":"10","author":"Yang","year":"2019","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1918986117","article-title":"ALKBH5 regulates anti\u2013PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment","volume":"117","author":"Li","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1038\/s41467-025-60293-4","article-title":"Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon response via MYC\/CDK2\/DNMT1 pathway","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1713615","article-title":"RBM15-mediated m6A modification in cancer progression and tumor immunity: Molecular mechanisms and therapeutic potential","volume":"13","author":"Li","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202501129","article-title":"DUX4-induced HSATII RNA accumulation drives protein aggregation, impacting RNA processing pathways","volume":"225","author":"Arends","year":"2026","journal-title":"J Cell Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf1204","article-title":"m6AConquer: A consistently quantified and orthogonally validated database for the N 6-methyladenosine (m6A) epitranscriptome","volume":"54","author":"Zhao","year":"2026","journal-title":"Nucleic Acids Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.stem.2017.11.016","article-title":"METTL14 inhibits hematopoietic stem\/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification","volume":"22","author":"Weng","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nature24678","article-title":"Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control","volume":"552","author":"Barbieri","year":"2017","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.351","article-title":"Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance","volume":"37","author":"Visvanathan","year":"2018","journal-title":"Oncogene"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.014","article-title":"N6-methyladenosine modulates messenger RNA translation efficiency","volume":"161","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"B73","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12943-022-01575-z","article-title":"M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma","volume":"21","author":"Du","year":"2022","journal-title":"Mol Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.11.006","article-title":"YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma","volume":"442","author":"Zhong","year":"2019","journal-title":"Cancer Lett"},{"key":"B75","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cell.2017.11.031","article-title":"R-2HG exhibits anti-tumor activity by targeting FTO\/m6A\/MYC\/CEBPA signaling","volume":"172","author":"Su","year":"2018","journal-title":"Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-020-01161-1","article-title":"m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107\/LATS2\u2013mediated YAP activity in NSCLC","volume":"19","author":"Jin","year":"2020","journal-title":"Mol Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07969-x","article-title":"RNA m5C oxidation by TET2 regulates chromatin state and leukaemogenesis","volume":"634","author":"Zou","year":"2024","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01505-w","article-title":"Quantitative sequencing using BID-seq uncovers abundant pseudouridines in mammalian mRNA at base resolution","volume":"41","author":"Dai","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000702","article-title":"Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs","volume":"80","author":"Hu","year":"2024","journal-title":"Hepatology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1016\/j.molcel.2021.06.031","article-title":"METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation","volume":"81","author":"Orellana","year":"2021","journal-title":"Mol Cell"},{"key":"B81","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13059-019-1873-2","article-title":"The majority of A-to-I RNA editing is not required for mammalian homeostasis","volume":"20","author":"Chalk","year":"2019","journal-title":"Genome Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1042\/BST20230727","article-title":"Suppression of double-stranded RNA sensing in cancer: Molecular mechanisms and therapeutic potential","volume":"52","author":"Young","year":"2024","journal-title":"Biochem Soc Trans"},{"key":"B83","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-022-04753-7","article-title":"ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis","volume":"606","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2023.149373","article-title":"ADAR-mediated RNA editing regulates PVR immune checkpoint in colorectal cancer","volume":"695","author":"Qian","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"B85","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jhep.2024.02.009","article-title":"CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma","volume":"81","author":"Xie","year":"2024","journal-title":"J Hepatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267866","article-title":"Tumor-infiltrating CCR2+ inflammatory monocytes counteract specific immunotherapy","volume":"14","author":"Bartneck","year":"2023","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-020-01165-x","article-title":"CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis","volume":"19","author":"Yang","year":"2020","journal-title":"Mol Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.812431","article-title":"Functional roles of chemokine receptor CCR2 and its ligands in liver disease","volume":"13","author":"She","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/JCI191422","article-title":"Targeting lactylation and the STAT3\/CCL2 axis to overcome immunotherapy resistance in pancreatic ductal adenocarcinoma","volume":"135","author":"Chen","year":"2025","journal-title":"J Clin Invest"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040872","article-title":"RNA-Seq analysis reveals CCR5 as a key target for CRISPR gene editing to regulate in vivo NK cell trafficking","volume":"13","author":"Levy","year":"2021","journal-title":"Cancers"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071765","article-title":"The CCL5\/CCR5 axis in cancer progression","volume":"12","author":"Aldinucci","year":"2020","journal-title":"Cancers"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2023-0190","article-title":"Nonsense-mediated mRNA decay, a simplified view of a complex mechanism","volume":"56","author":"Carrard","year":"2023","journal-title":"BMB Rep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/genes14020357","article-title":"Nonsense-mediated mRNA decay as a mediator of tumorigenesis","volume":"14","author":"Nagar","year":"2023","journal-title":"Genes"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3664","article-title":"The rules and impact of nonsense-mediated mRNA decay in human cancers","volume":"48","author":"Lindeboom","year":"2016","journal-title":"Nat Genet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-024-01267-7","article-title":"Nonsense-mediated mRNA decay in human health and diseases: Current understanding, regulatory mechanisms and future perspectives","volume":"67","author":"Behera","year":"2025","journal-title":"Mol Biotechnol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1104104108","article-title":"Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation","volume":"108","author":"Apcher","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001605","article-title":"GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses","volume":"84","author":"Jiang","year":"2025","journal-title":"Hepatology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.molcel.2020.10.019","article-title":"Poison exon splicing regulates a coordinated network of SR protein expression during differentiation and tumorigenesis","volume":"80","author":"Leclair","year":"2020","journal-title":"Mol Cell"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111404","article-title":"FOXA1 regulates alternative splicing in prostate cancer","volume":"40","author":"Del Giudice","year":"2022","journal-title":"Cell Rep"},{"key":"B101","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.trecan.2024.10.008","article-title":"Generation of tumor neoantigens by RNA splicing perturbation","volume":"11","author":"Rosenberg-Mogilevsky","year":"2025","journal-title":"Trends Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1038\/s41467-022-30181-2","article-title":"Regulation of A-to-I RNA editing and stop codon recoding to control selenoprotein expression during skeletal myogenesis","volume":"13","author":"Noda","year":"2022","journal-title":"Nat Commun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2016.1201628","article-title":"m6A: Signaling for mRNA splicing","volume":"13","author":"Adhikari","year":"2016","journal-title":"RNA Biol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf700","article-title":"Widespread 3\u2032 UTR splicing regulates expression of oncogene transcripts through multiple mechanisms","volume":"53","author":"Riley","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.09.044","article-title":"CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma","volume":"82","author":"Lu","year":"2025","journal-title":"J Hepatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2017.016","article-title":"Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening","volume":"12","author":"Joung","year":"2017","journal-title":"Nat Protoc"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-025-01199-0","article-title":"Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma","volume":"35","author":"Zhao","year":"2025","journal-title":"Cell Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1655273","article-title":"The role of the 3\u2032-UTR of the chemokine receptor CCR2 and hnRNPA0 in regulating mRNA stability and subcellular distribution in human CD4+ T cells","volume":"16","author":"Yukselten","year":"2025","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol J"},{"key":"B110","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri3622","article-title":"Regulation of immune responses by extracellular vesicles","volume":"14","author":"Robbins","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12967-023-04553-1","article-title":"Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy","volume":"21","author":"Zhao","year":"2023","journal-title":"J Transl Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202313226","article-title":"Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy","volume":"36","author":"Metzloff","year":"2024","journal-title":"Adv Mater"},{"key":"B113","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.1038\/s41467-025-62506-2","article-title":"Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles","volume":"16","author":"Xiao","year":"2025","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2026.02.020","article-title":"Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological Malignancies","volume":"34","author":"Lemgart","year":"2026","journal-title":"Mol Ther"},{"key":"B116","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-8097564\/v1","article-title":"Delivering cytokine mRNA to secondary lymphoid organs for robust cancer immunotherapy","volume-title":"In Review","author":"Mulder","year":"2026"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2504976123","article-title":"Self-adjuvanting \u03b1-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors","volume":"123","author":"Han","year":"2026","journal-title":"Proc Natl Acad Sci USA"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10353-6","article-title":"mRNA vaccines engage unconventional pathways in CD8+ T cell priming","volume":"654","author":"Jo","year":"2026","journal-title":"Nature"},{"key":"B119","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","article-title":"Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors","volume":"173","author":"Konermann","year":"2018","journal-title":"Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01609","article-title":"A chemically induced CRISPR\/dCas13 platform for precise and programmable RNA regulation","volume":"68","author":"Hasselbeck","year":"2025","journal-title":"J Med Chem"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.cell.2024.01.035","article-title":"A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells","volume":"187","author":"Tieu","year":"2024","journal-title":"Cell"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111226","article-title":"Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells","volume":"40","author":"Kelley","year":"2022","journal-title":"Cell Rep"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2022.102789","article-title":"The double life of CRISPR-Cas13","volume":"78","author":"Bot","year":"2022","journal-title":"Curr Opin Biotechnol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/genes16101168","article-title":"RNA-targeting techniques: A comparative analysis of modern approaches for RNA manipulation in cancer research and therapeutics","volume":"16","author":"Boti","year":"2025","journal-title":"Genes"},{"key":"B126","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1038\/s41467-021-24470-5","article-title":"Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease","volume":"12","author":"Sahoo","year":"2021","journal-title":"Nat Commun"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188548","article-title":"A primer on applying AI synergistically with domain expertise to oncology","volume":"1876","author":"Kim","year":"2021","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B128","doi-asserted-by":"publisher","first-page":"7269","DOI":"10.1038\/s41467-025-62647-4","article-title":"Sensitive neoantigen discovery by real-time mutanome-guided immunopeptidomics","volume":"16","author":"Shapiro","year":"2025","journal-title":"Nat Commun"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","article-title":"MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing","volume":"11","author":"O\u2019Donnell","year":"2020","journal-title":"Cell Syst"},{"key":"B131","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13073-025-01514-9","article-title":"SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics","volume":"17","author":"Testa","year":"2025","journal-title":"Genome Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1002\/qub2.78","article-title":"Bioinformatics perspectives on transcriptomics: A comprehensive review of bulk and single\u2010cell RNA sequencing analyses","volume":"13","author":"Tzec\u2010Interi\u00e1n","year":"2025","journal-title":"Quant Biol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41467-026-68651-6","article-title":"NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes","volume":"17","author":"Lee","year":"2026","journal-title":"Nat Commun"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1722117","article-title":"CNNeoPP: a large language model-enhanced deep learning pipeline for personalized neoantigen prediction and liquid biopsy applications","volume":"17","author":"Cai","year":"2026","journal-title":"Front Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wrna.100","article-title":"Evolution of SR protein and hnRNP splicing regulatory factors","volume":"3","author":"Busch","year":"2012","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-062124-035809","article-title":"RNA splicing as a therapeutic target in cancer","volume":"66","author":"Lewis","year":"2026","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1152087","article-title":"Targeting pre-mRNA splicing in cancers: roles, inhibitors, and therapeutic opportunities","volume":"13","author":"Araki","year":"2023","journal-title":"Front Oncol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2025.9036","article-title":"Alternative splicing in cancer drug resistance: Mechanisms and therapeutic prospects (Review)","volume":"55","author":"Zhu","year":"2026","journal-title":"Oncol Rep"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0350-x","article-title":"Roles and mechanisms of alternative splicing in cancer \u2014 implications for care","volume":"17","author":"Bonnal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03279-w","article-title":"Targeting RNA splicing modulation: new perspectives for anticancer strategy","volume":"44","author":"Lv","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6c00234","article-title":"Recent advances in targeting RNA splicing factors with small molecules","volume":"69","author":"Yuan","year":"2026","journal-title":"J Med Chem"},{"key":"B142","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11033-025-11302-8","article-title":"Rewiring the transcriptome: diagnostic and therapeutic implications of alternative splicing in solid cancers","volume":"53","author":"Ebrahim","year":"2025","journal-title":"Mol Biol Rep"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060789","article-title":"Alternative splicing in tumorigenesis and cancer therapy","volume":"15","author":"Chen","year":"2025","journal-title":"Biomolecules"},{"key":"B144","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41576-025-00928-w","article-title":"Regulation of gene expression by alternative polyadenylation in health and disease","volume":"27","author":"Tian","year":"2026","journal-title":"Nat Rev Genet"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-026-01720-9","article-title":"Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer","author":"Huang","year":"2026","journal-title":"Nat BioMed Eng"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-025-01464-0","article-title":"CSTF2-impeded innate ?? T cell infiltration and activation exacerbate immune evasion of pancreatic cancer","volume":"32","author":"He","year":"2025","journal-title":"Cell Death Differ"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202518346","article-title":"NUDT21-mediated alternative polyadenylation of CDK19 reprograms cholesterol biosynthesis to drive colorectal cancer progression","volume":"13","author":"Yu","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1101\/gr.271635.120","article-title":"Acute depletion of METTL3 implicates N6-methyladenosine in alternative intron\/exon inclusion in the nascent transcriptome","volume":"31","author":"Wei","year":"2021","journal-title":"Genome Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020105977","article-title":"m6 A RNA methylation: from mechanisms to therapeutic potential","volume":"40","author":"He","year":"2021","journal-title":"EMBO J"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.45231","article-title":"Function and evolution of RNA N6-methyladenosine modification","volume":"16","author":"Zhu","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B151","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11033-025-11248-x","article-title":"Mettl3 in colorectal cancer: molecular insights and clinical implications","volume":"53","author":"Lagunas-Rangel","year":"2025","journal-title":"Mol Biol Rep"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-026-05679-8","article-title":"Mettl3 promotes proliferation and invasion and inhibits ferroptosis in hepatocellular carcinoma by mediating m6A methylation modification of NUPR1","author":"Zhao","year":"2026","journal-title":"Mol Cell Biochem"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1186\/s40001-025-03351-3","article-title":"The role and mechanism of METTL3 in cancer: emerging insights into m6A methylation and therapeutic potential","volume":"30","author":"Yuan","year":"2025","journal-title":"Eur J Med Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01403","article-title":"Multiple functions and mechanisms underlying the role of METTL3 in human cancers","volume":"9","author":"Zheng","year":"2019","journal-title":"Front Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01570","article-title":"Small-molecule inhibitors targeting RNA m6A modifiers for cancer therapeutics: latest advances and future perspectives","volume":"68","author":"Tang","year":"2025","journal-title":"J Med Chem"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2024.2447056","article-title":"Patent landscape of small molecule inhibitors of METTL3 (2020-present)","volume":"35","author":"Wu","year":"2024","journal-title":"Expert Opin Ther Pat"},{"key":"B157","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114165","article-title":"Small-molecule inhibition of the METTL3\/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation","volume":"43","author":"Pomaville","year":"2024","journal-title":"Cell Rep"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0345744","article-title":"The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification","volume":"21","author":"Sun","year":"2026","journal-title":"PloS One"},{"key":"B160","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1021\/acs.jmedchem.4c02225","article-title":"Discovery, optimization, and preclinical pharmacology of EP652, a METTL3 inhibitor with efficacy in liquid and solid tumor models","volume":"68","author":"Dutheuil","year":"2025","journal-title":"J Med Chem"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3390\/ph19070990","article-title":"M1A and m6A RNA methylations as druggable targets in cancer","volume":"19","author":"Gazalo\u011flu","year":"2026","journal-title":"Pharm (Basel)"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1261\/rna.079988.124","article-title":"Understanding the redundant functions of the m6A-binding YTHDF proteins","volume":"30","author":"Zaccara","year":"2024","journal-title":"RNA"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2024.04.001","article-title":"The YTHDF proteins display distinct cellular functions on m6A-modified RNA","volume":"49","author":"Zou","year":"2024","journal-title":"Trends Biochem Sci"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001292","article-title":"N6-methyladenosine promotes induction of ADAR1-mediated A-to-I RNA editing to suppress aberrant antiviral innate immune responses","volume":"19","author":"Terajima","year":"2021","journal-title":"PloS Biol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13059-021-02271-9","article-title":"ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism","volume":"22","author":"Tassinari","year":"2021","journal-title":"Genome Biol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70208","article-title":"A wonderful journey: The diverse roles of adenosine deaminase acting on RNA 1 (ADAR1) in central nervous system diseases","volume":"31","author":"Cheng","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04974-w","article-title":"ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation","volume":"607","author":"De Reuver","year":"2022","journal-title":"Nature"},{"key":"B168","doi-asserted-by":"publisher","first-page":"6297","DOI":"10.1038\/s41467-026-72271-5","article-title":"All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer","volume":"17","author":"Li","year":"2026","journal-title":"Nat Commun"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/2326-6066.CIR-25-1626","article-title":"ADAR1 deficiency in pancreatic cancer cells potentiates cDC1 activation and promotes sensitization to immunotherapy","volume":"14","author":"Li","year":"2026","journal-title":"Cancer Immunol Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218071","article-title":"Loss of ADAR1 in lung cancer activates anti-tumour immunity and suppresses tumour cell growth via the RIG-I\/MDA5-MAVS pathway","volume":"635","author":"Jia","year":"2025","journal-title":"Cancer Lett"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00481-2","article-title":"Nonsense-mediated RNA decay: an emerging modulator of Malignancy","volume":"22","author":"Tan","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s11033-026-12371-z","article-title":"Nonsense-mediated mRNA decay as a gatekeeper of neoantigen expression: bridging RNA surveillance and tumor immunotherapy","volume":"53","author":"Majumder","year":"2026","journal-title":"Mol Biol Rep"},{"key":"B173","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12943-021-01364-0","article-title":"Nonsense-mediated RNA decay and its bipolar function in cancer","volume":"20","author":"Nogueira","year":"2021","journal-title":"Mol Cancer"},{"key":"B174","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12964-026-02979-w","article-title":"Nonsense-mediated mRNA decay: friend or foe in cancer biology","volume":"24","author":"Wang","year":"2026","journal-title":"Cell Commun Signal"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/s44318-026-00794-0","article-title":"Beyond quality control: biological roles of nonsense-mediated RNA decay","volume":"45","author":"Tan","year":"2026","journal-title":"EMBO J"},{"key":"B176","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-3-030-19966-1_3","article-title":"Nonsense-mediated mRNA decay in development, stress and cancer","volume":"1157","author":"Fernandes","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.semcdb.2017.08.053","article-title":"Beyond quality control: The role of nonsense-mediated mRNA decay (NMD) in regulating gene expression","volume":"75","author":"Nasif","year":"2018","journal-title":"Semin Cell Dev Biol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s13046-021-02192-2","article-title":"Deciphering the nonsense-mediated mRNA decay pathway to identify cancer cell vulnerabilities for effective cancer therapy","volume":"40","author":"Bongiorno","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030765","article-title":"Nonsense-mediated mRNA decay: pathologies and the potential for novel therapeutics","volume":"12","author":"Pawlicka","year":"2020","journal-title":"Cancers"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-4016","article-title":"Nonsense-mediated RNA decay is a unique vulnerability of cancer cells harboring SF3B1 or U2AF1 mutations","volume":"81","author":"Cheruiyot","year":"2021","journal-title":"Cancer Res"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s41467-019-09903-6","article-title":"Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1002\/advs.76143","article-title":"Single-cell RNA editing identifies T cell ADAR1 as a key regulator of immune exhaustion and anti-PD-1 resistance in colorectal cancer","author":"Kang","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01126","article-title":"Reduced expression of METTL3 promotes metastasis of triple-negative breast cancer by m6A methylation-mediated COL3A1 up-regulation","volume":"10","author":"Shi","year":"2020","journal-title":"Front Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0007","article-title":"Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity","volume":"13","author":"Guirguis","year":"2023","journal-title":"Cancer Discov"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102389","article-title":"NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes","volume":"24","author":"Becker","year":"2021","journal-title":"iScience"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404461","article-title":"5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion","volume":"6","author":"Bhuvanagiri","year":"2014","journal-title":"EMBO Mol Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1889279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:14:20Z","timestamp":1789553660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1889279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":186,"alternative-id":["10.3389\/fimmu.2026.1889279"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1889279","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1889279"}}